Use of Steroid Profiling by UPLC-MS/MS as a Second Tier Test in Newborn Screening for Congenital Adrenal Hyperplasia: The Utah Experience
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Newborn screening allows the diagnosis of congenital adrenal hyperplasia (CAH) before symptoms appear, preventing the severe and potentially life-threatening crisis associated with this disease in infancy. Traditional screening by enzyme immunoassay results in a large number of false positives. To reduce the number of unnecessary tests, anxiety to families and physicians, and the burden to the newborn screening follow-up program, we implemented a second-tier test for CAH using steroid profiling by an ultra-performance liquid chromatography-tandem mass spectrometry. We measured three steroids: 17-hydroxyprogesterone, androstenedione, and cortisol and correlated them with the age of infant at the time of sample collection and birth weight. Both age at collection and birth weight affected the levels of adrenal steroids, but the use of appropriate cut offs and analyte ratios allowed the identification of infants with CAH. This approach was effective in identifying infants with CAH, with both salt-wasting and simple virilizing forms, while reducing the false-positive rate from 2.6 to 0.09%.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, others have reported markedly superior results with LC-MS/MS (83,84).”
From Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society* Clinical Practice Guideline (2018) · cites this paper as [83]
Citations
Cites
Congenital Adrenal Hyperplasia
(1987) · New England Journal of Medicine · doi:10.1056/nejm198711263172211 · Cited by 1,409
Congenital adrenal hyperplasia
Speiser, P. W., & White, P. C. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021561 · Cited by 1,405
Pang, S., Wallace, M. A., Hofman, L., Thuline, H. C., Dorche, C., Lyon, I. C. T., Dobbins, R. H., Kling, S., Fujieda, K., & Suwa, S. (1988) · Journal of Urology · doi:10.1016/s0022-5347(17)42164-1 · Cited by 392
Therrell, B. L., Berenbaum, S. A., Manter-Kapanke, V., Simmank, J., Korman, K., Prentice, L., Gonzalez, J., & Gunn, S. (1998) · Pediatrics · doi:10.1542/peds.101.4.583 · Cited by 344
Lacey, J. M., Minutti, C. Z., Magera, M. J., Tauscher, A. L., Casetta, B., McCann, M., Lymp, J., Hahn, S. H., Rinaldo, P., & Matern, D. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2003.027193 · Cited by 216 · cited 1×
“In this study, we simplify the extraction and optimize the quantitation of 17-OHP, androstenedione, and cortisol to improve an existing method (21,22).”
MethodJanzen, N., Peter, M., Sander, S., Steuerwald, U., Terhardt, M., Holtkamp, U., & Sander, J. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2890 · Cited by 211 · cited 4×
“ratios using these steroids have been shown to be helpful in identifying these infants (23,24).”
BackgroundMethodInfluentialRauh, M., Gröschl, M., Rascher, W., & Dörr, H. G. (2006) · Steroids · doi:10.1016/j.steroids.2006.01.015 · Cited by 170
Minutti, C. Z., Lacey, J. M., Magera, M. J., Hahn, S. H., McCann, M., Schulze, A., Cheillan, D., Dorche, C., Chace, D. H., Lymp, J. F., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032235 · Cited by 154 · cited 2×
“In this study, we simplify the extraction and optimize the quantitation of 17-OHP, androstenedione, and cortisol to improve an existing method (21,22).”
BackgroundMethodAllen, D. B., Hoffman, G. L., Fitzpatrick, P., Laessig, R., Maby, S., & Slyper, A. (1997) · The Journal of Pediatrics · doi:10.1016/s0022-3476(97)70321-4 · Cited by 153
Adrenal Function in Sick Very Preterm Infants
Huysman, M. W. A., Hokken-Koelega, A., de Ridder, M. A. J., & Sauer, P. J. J. (2000) · Pediatric Research · doi:10.1203/00006450-200011000-00013 · Cited by 152 · cited 1×
“improves the specificity of the test (8,9).”
Research works printed but not linked: 3
- Pang SY, 1988, Pediatrics, 81, 866
- Kao PC, 2001, Ann Clin Lab Sci, 31, 199
- Caulfield MP, 2002, J Clin Endocrinol Metab, 87, 3682, 10.1210/jc.87.8.3682 · doi:10.1210/jc.87.8.3682 · Paper page
Cited by
Speiser, P. W., Azziz, R., Baskin, L. S., Ghizzoni, L., Hensle, T. W., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Montori, V. M., Oberfield, S. E., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2631 · Cited by 1,468
“Genotyping is more costly than LC-MS/MS on a per-sample basis.”
InfluentialSpeiser, P. W., Arlt, W., Auchus, R. J., Baskin, L. S., Conway, G. S., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Murad, M. H., Oberfield, S. E., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01865 · Cited by 1,234
Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management
Claahsen - van der Grinten, H. L., Speiser, P. W., Ahmed, S. F., Arlt, W., Auchus, R. J., Falhammar, H., Flück, C. E., Guasti, L., Huebner, A., Kortmann, B. B. M., et al. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab016 · Cited by 556
Mass spectrometry and immunoassay: how to measure steroid hormones today and tomorrow
Taylor, A. E., Keevil, B., & Huhtaniemi, I. T. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0338 · Cited by 320
PW, S., W, A., RJ, A., LS, B., GS, C., DP, M., HFL, M.-B., WL, M., MH, M., SE, O., et al. (2019) · Yearbook of Paediatric Endocrinology · doi:10.1530/ey.16.8.5 · Cited by 300
The use of mass spectrometry to analyze dried blood spots
Wagner, M., Tonoli, D., Varesio, E., & Hopfgartner, G. (2016) · Mass Spectrometry Reviews · doi:10.1002/mas.21441 · Cited by 262
“, 2011), MeCN/H2O (8:2, v/v) (Schwarz et al., 2009), or MeOH/H2O (9:1, v/v) (Dhillon et al.”
MethodLiquid chromatography tandem mass spectrometry for analysis of steroids in clinical laboratories
Kushnir, M. M., Rockwood, A. L., Roberts, W. L., Yue, B., Bergquist, J., & Meikle, A. W. (2011) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2010.07.008 · Cited by 228
Shackleton, C. (2010) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2010.02.017 · Cited by 226
Inborn errors of metabolism and expanded newborn screening: review and update
Mak, C. M., Lee, H.-C. H., Chan, A. Y.-W., & Lam, C.-W. (2013) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2013.847896 · Cited by 201
Kulle, A. E., Riepe, F. G., Melchior, D., Hiort, O., & Holterhus, P. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1670 · Cited by 182
“Of note, screening methods using dried blood on filter cards (14, 23) need a sample volume of only 15 l by a significantly higher (up to about 10 times) limit of quantification (14).”
MethodAdrenal Steroidogenesis and Congenital Adrenal Hyperplasia
Turcu, A. F., & Auchus, R. J. (2015) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2015.02.002 · Cited by 177
LC–MS based analysis of endogenous steroid hormones in human hair
Gao, W., Kirschbaum, C., Graß, J., & Stalder, T. (2015) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2015.12.022 · Cited by 175
Expanded newborn screening by mass spectrometry: New tests, future perspectives
Ombrone, D., Giocaliere, E., Forni, G., Malvagia, S., & la Marca, G. (2015) · Mass Spectrometry Reviews · doi:10.1002/mas.21463 · Cited by 154
“screens and by using MS/MS in the second-tier tests, the specificity of NBS results improve (Schwarz et al., 2009), although not completely eliminating false-positive results but this benefit is opposed by the increased risk of false negatives as reported by Sarafoglou et al.”
ResultGosetti, F., Mazzucco, E., Gennaro, M. C., & Marengo, E. (2012) · Journal of Chromatography B · doi:10.1016/j.jchromb.2012.12.003 · Cited by 138
Steroid measurement with LC–MS/MS. Application examples in pediatrics
Rauh, M. (2009) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2009.12.007 · Cited by 113
A review of clinical diagnostic applications of liquid chromatography–tandem mass spectrometry
Shushan, B. I. (2010) · Mass Spectrometry Reviews · doi:10.1002/mas.20295 · Cited by 105
Pitt, J. J. (2010) · Europe PMC (PubMed Central) · Cited by 155
Dénes, J., Szabó, E., Robinette, S. L., Szatmári, I., Szönyi, L., Kreuder, J. G., Rauterberg, E. W., & Takáts, Z. (2012) · Analytical Chemistry · doi:10.1021/ac302527m · Cited by 89
Abdel‐Khalik, J., Björklund, E., & Hansen, M. A. (2013) · Journal of Chromatography B · doi:10.1016/j.jchromb.2013.03.013 · Cited by 82
An untargeted metabolomics method for archived newborn dried blood spots in epidemiologic studies
Petrick, L. M., Edmands, W. M. B., Schiffman, C., Grigoryan, H., Perttula, K., Yano, Y., Dudoit, S., Whitehead, T. P., Metayer, C., & Rappaport, S. M. (2017) · Metabolomics · doi:10.1007/s11306-016-1153-z · Cited by 80
“Although several steroids including progesterone, 17-hydroxyprogesterone (17-OHP), cortisol, and growth hormones have been found to be inversely associated with infant birth weight, newborn hormone levels are influenced by many factors such as delivery type, gestational age, maternal height, maternal hormone levels, a…”
Denoroy, L., Zimmer, L., Renaud, B., & Parrot, S. (2012) · Journal of Chromatography B · doi:10.1016/j.jchromb.2012.12.005 · Cited by 82
The next 150 years of congenital adrenal hyperplasia
Turcu, A. F., & Auchus, R. J. (2015) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2015.05.013 · Cited by 70
Newborn screening for congenital adrenal hyperplasia in New Zealand, 1994-2013
Heather, N. L., Seneviratne, S. N., Webster, D., Derraik, J. G. B., Jefferies, C., Carll, J., Jiang, Y., Cutfield, W. S., & Hofman, P. L. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3168 · Cited by 65
Newborn Screening for Congenital Adrenal Hyperplasia: Review of Factors Affecting Screening Accuracy
Held, P. K., Bird, I. M., & Heather, N. L. (2020) · International Journal of Neonatal Screening · doi:10.3390/ijns6030067 · Cited by 79
“Various combinations of individual steroid concentrations and ratios have been demonstrated to enhance screening specificity, decreasing false positive rates by as much as 90% [28,29].”
BackgroundIncidence and clinical features of congenital adrenal hyperplasia in Great Britain
Khalid, J. M., Oerton, J. M., Dezateux, C., Hindmarsh, P. C., Kelnar, C. J., & Knowles, R. L. (2012) · Archives of Disease in Childhood · doi:10.1136/archdischild-2011-300234 · Cited by 64
Seo, J. Y., Park, H.-D., Kim, J. W., Oh, H. J., Yang, J. S., Chang, Y. S., Park, W. S., & Lee, S.-Y. (2014) · jpme · doi:10.1515/jpm-2013-0154 · Cited by 55
Rapidity and Precision of Steroid Hormone Measurement
Karashima, S., & Osaka, I. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11040956 · Cited by 63
“[106] reported a method for identifying infants with CAH by analyzing 17-hydroxyprogesterone, androstenedione, and cortisol using LC-MS/MS.”
MethodDevelopment of Strategies to Decrease False Positive Results in Newborn Screening
Malvagia, S., Forni, G., Ombrone, D., & la Marca, G. (2020) · International Journal of Neonatal Screening · doi:10.3390/ijns6040084 · Cited by 67
“Recently, many laboratories have decided to perform a 2-TT using steroid hormone profiling by LC-MS/MS which can reveal the characteristic diagnostic pattern of elevated 17-OHP, high androstenedione level and low cortisol, thus improving the PPV of CAH screening programs [39,40].”
BackgroundChallenges for Worldwide Harmonization of Newborn Screening Programs
Martínez‐Morillo, E., García, B. P., & Menéndez, F. V. Á. (2016) · Clinical Chemistry · doi:10.1373/clinchem.2015.240903 · Cited by 50
“However, the PPV in preterm infants was only 1.4% (39).”
MethodInfluentialChallenges and Benefits of Endogenous Steroid Analysis by LC–MS/MS
Couchman, L., Vincent, R. P., Ghataore, L., Moniz, C. F., & Taylor, N. (2011) · Bioanalysis · doi:10.4155/bio.11.254 · Cited by 47
Janzen, N., Riepe, F. G., Peter, M., Sander, S., Steuerwald, U., Korsch, E., Krull, F., Müller, H. L., Heger, S., Brack, C., et al. (2012) · Hormone Research in Paediatrics · doi:10.1159/000337974 · Cited by 37
How mass spectrometry revolutionized newborn screening
Millington, D. S. (2024) · Journal of Mass Spectrometry and Advances in the Clinical Lab · doi:10.1016/j.jmsacl.2024.01.006 · Cited by 47
“…of all presumptive positives, specifically targeting the steroids in the metabolic pathway using UPLC-MS/ MS with stable-isotope-labelled internal standards[35], the false positive rate was cut by a factor of 30, improving the accuracy, and saving unnecessary costs and parental anxiety [36].”
MethodGuidelines for diagnosis and treatment of 21-hydroxylase deficiency (2014 revision)
Ishii, T., Anzo, M., Adachi, M., Onigata, K., Kusuda, S., Nagasaki, K., Harada, S., Horikawa, R., Minagawa, M., Minamitani, K., et al. (2015) · Clinical Pediatric Endocrinology · doi:10.1297/cpe.24.77 · Cited by 40
Kopacek, C., de Castro, S. M., Prado, M. J., da Silva, C. M. D., Beltrão, L. A., & Spritzer, P. M. (2017) · BMC Pediatrics · doi:10.1186/s12887-016-0772-x · Cited by 36
Turcu, A. F., El-Maouche, D., Zhao, L., Nanba, A. T., Gaynor, A., Veeraraghavan, P., Auchus, R. J., & Merke, D. P. (2020) · European Journal of Endocrinology · doi:10.1530/eje-20-0129 · Cited by 33
Diagnosis of Diseases of Steroid Hormone Production, Metabolism and Action
Honour, J. W. (2009) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.v1i5.209 · Cited by 32
“Screening will also improve with more specific technology based on tandem mass spectrometry (117-119).”
BackgroundClinical guidelines for the diagnosis and treatment of 21-hydroxylase deficiency (2021 revision)
Ishii, T., Kashimada, K., Amano, N., Takasawa, K., Nakamura‐Utsunomiya, A., Yatsuga, S., Mukai, T., Ida, S., Isobe, M., Fukushi, M., et al. (2022) · Clinical Pediatric Endocrinology · doi:10.1297/cpe.2022-0009 · Cited by 37
Steroid Assays in Paediatric Endocrinology
Honour, J. W. (2010) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.v2i1.1 · Cited by 33
Outcome of Newborn Screening for Congenital Adrenal Hyperplasia at Two Time Points
Eshragh, N., Doan, L. V., Connelly, K. J., Denniston, S., Willis, S., & LAFRANCHI, S. H. (2020) · Hormone Research in Paediatrics · doi:10.1159/000508075 · Cited by 30
de Hora, M. R., Heather, N. L., Patel, T., Bresnahan, L. G., WEBSTER, D. R., & Hofman, P. L. (2020) · International Journal of Neonatal Screening · doi:10.3390/ijns6010006 · Cited by 29
“The use of 17OHP and androstenedione expressed as a ratio to cortisol has been used as additional secondary marker in CAH [14,19,20].”
MethodHird, B. E., Tetlow, L., Tobi, S., Patel, L., & Clayton, P. E. (2014) · Archives of Disease in Childhood · doi:10.1136/archdischild-2013-304473 · Cited by 25
Bialk, E. R., Lasarev, M. R., & Held, P. K. (2019) · International Journal of Neonatal Screening · doi:10.3390/ijns5030033 · Cited by 25
“Modifications to this original method, eliminating the diethyl ether extraction, were published by other state newborn screening programs; however, states continued to only quantify cortisol, 17-OHP, and androstenedione [16,17].”
MethodNewborn Screening and Diagnosis of Infants with Congenital Adrenal Hyperplasia
Vats, P., Dabas, A., Jain, V., Seth, A., Yadav, S., Kabra, M., Gupta, N., Singh, P., Sharma, R., Kumar, R., et al. (2020) · Indian Pediatrics · doi:10.1007/s13312-020-1703-3 · Cited by 27
Neonatal mass screening for 21-hydroxylase deficiency
Tajima, T., & Fukushi, M. (2016) · Clinical Pediatric Endocrinology · doi:10.1297/cpe.25.1 · Cited by 24
“(32) reported the results of LC-MS/MS as a second-tier test in MS for CAH from Utah, USA.”
BackgroundRussian clinical practice guidelines «congenital adrenal hyperplasia»
Mokrysheva, N. G., Mel'nichenko, G. A., Adamyan, L. V., Troshina, E. A., Молашенко, Н. В., Игоревна, С. А., Uvarova, E. V., Esayan, E. R. M., Andreeva, E. N., Ужегова, Ж. А., et al. (2021) · Obesity and metabolism · doi:10.14341/omet12787 · Cited by 30
Sarafoglou, K., Himes, J. H., Lacey, J. M., Netzel, B. C., Singh, R. J., & Matern, D. (2010) · Hormone Research in Paediatrics · doi:10.1159/000315910 · Cited by 21
Pilot proficiency testing study for second tier congenital adrenal hyperplasia newborn screening
De Jesús, V. R., Simms, D. A., Schiffer, J., Kennedy, M., Mei, J. V., & Hannon, W. H. (2010) · Clinica Chimica Acta · doi:10.1016/j.cca.2010.06.029 · Cited by 20
Application of principal component analysis to newborn screening for congenital adrenal hyperplasia
Lasarev, M. R., Bialk, E. R., Allen, D. B., & Held, P. K. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa371 · Cited by 19
21-Deoxycortisol is a Key Screening Marker for 21-Hydroxylase Deficiency
Held, P. K., Bialk, E. R., Lasarev, M. R., & Allen, D. B. (2021) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2021.10.063 · Cited by 23
Greene, C. N., Cordovado, S. K., Turner, D. P., Keong, L. M., Shulman, D., & Mueller, P. W. (2014) · Molecular Genetics and Metabolism Reports · doi:10.1016/j.ymgmr.2014.07.002 · Cited by 19
“The first is the use of second-tier liquid chromatography tandem mass spectrophotometry (LC-MS/MS) methods to compare steroid profile measurements in the DBS specimen to increase testing accuracy [10–13].”
MethodHall, P., Wittenauer, A., & Hagar, A. F. (2014) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2014.10.007 · Cited by 19
Han, L., Tavakoli, N. P., Morrissey, M., Spink, D. C., & Cao, Z. (. (2019) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-018-1449-0 · Cited by 16
Role of Mass Spectrometry in Clinical Endocrinology
Ketha, S. S., Singh, R. J., & Ketha, H. (2017) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2017.04.001 · Cited by 17
de Hora, M. R., Heather, N. L., Patel, T., Bresnahan, L. G., WEBSTER, D. R., & Hofman, P. L. (2021) · Clinical Endocrinology · doi:10.1111/cen.14422 · Cited by 17
de Hora, M. R., Heather, N. L., WEBSTER, D. R., Albert, B. B., & Hofman, P. L. (2022) · International Journal of Neonatal Screening · doi:10.3390/ijns8040056 · Cited by 17
“Several studies had shown that (17OHP + A4)/F offers improvements to screening specificity [6], but there is a risk of reducing sensitivity unless appropriate cut-offs are established [17,18].”
BackgroundMethodTherapy monitoring in congenital adrenal hyperplasia by dried blood samples
Wieacker, I., Peter, M., Borucki, K., Empting, S., Roehl, F.-W., & Mohnike, K. (2015) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2014-0303 · Cited by 14
Fernández, B. H., Fernández, M. E., Íñiguez, E. D., Zubicaray, B. E., Martín, M. B. R., Arnao, M. D. R., & Sánchez, A. R. (2011) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem.2011.007 · Cited by 16
“Other limitations include the unavailability of methods to extract 17-OHP, or other methods such as detailed estroid profi ling or more specifi c assays such as tandem mass spectrometry (39, 40) to confi rm increased 17-OHP.”
Agnani, H., Bachelot, G., Eguether, T., Ribault, B., Fiet, J., Bouc, Y. L., Netchine, I., Houang, M., & Lamazière, A. (2022) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2022.106085 · Cited by 13
Tandem Mass Spectrometry in Hormone Measurement
Field, H. P. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-616-0_4 · Cited by 14
Su, M., Drotleff, B., Janker, T., Bürger, Z., Kimmig, A.-C. S., Derntl, B., & Lämmerhofer, M. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.5c01912 · Cited by 14
Kim, M. S., Koppin, C. M., Mohan, P., Goodarzian, F., Ross, H., Geffner, M. E., Filippo, R. D., & Kokorowski, P. K. (2019) · Hormone Research in Paediatrics · doi:10.1159/000504135 · Cited by 11
“ovarian regions in females with poorly controlled CAH [19].”
BackgroundLi, Z., Liang, Y., Du, C., Xiao, Y., Hou, L., Wu, W., Ying, Y., & Luo, X. (2021) · BMC Endocrine Disorders · doi:10.1186/s12902-021-00901-8 · Cited by 12
de Hora, M. R., Heather, N. L., WEBSTER, D. R., Albert, B. B., & Hofman, P. L. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1226284 · Cited by 15
Younesi, S., Yazdani, B., Amin, M. M. T., Saadati, P., Jamali, S., Modarresi, M., Savad, S., Amidi, S., Razavi, H., & Ghafouri‐Fard, S. (2022) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24471 · Cited by 10
Newborn Screening By Tandem Mass Spectrometry: Impacts, Implications and Perspectives
Rousseau, F., Giguere, Y., Berthier, M., Guérette, D., Girard, J.-G., & Dry, M. (2012) · InTech eBooks · doi:10.5772/33118 · Cited by 9
“The ratio of (17 OH-P + androstenedione)/cortisol, increases discrimination since 17-OH-P and androstenedione are increased while cortisol is decreased in CAH (Schwarz et al., 2009; Lacey et al., 2004; Minutti et al., 2004).”
de Hora, M. R., Heather, N. L., WEBSTER, D. R., Albert, B. B., & Hofman, P. L. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab383 · Cited by 11
International Newborn Screening Practices for the Early Detection of Congenital Adrenal Hyperplasia
Conlon, T. A., Hawkes, C. P., Brady, J. J., Loeber, J. G., & Murphy, N. (2023) · Hormone Research in Paediatrics · doi:10.1159/000530754 · Cited by 8
Qasrawi, D. O., Boyd, J. M., & Sadrzadeh, S. M. H. (2021) · Clinica Chimica Acta · doi:10.1016/j.cca.2021.06.005 · Cited by 11
Le dépistage néonatal de l’hyperplasie congénitale des glandes surrénales
Kariyawasam, D., Nguyen‐Khoa, T., Briceño, L. G., & Polak, M. (2021) · médecine/sciences · doi:10.1051/medsci/2021060 · Cited by 10
de Castro, S. M., Wiest, P., Spritzer, P. M., & Kopacek, C. (2023) · Endocrine Connections · doi:10.1530/ec-23-0162 · Cited by 9
“Congenital adrenal hyperplasia (CAH) is an autosomal recessive disorder characterized by inadequate cortisol secretion (with or without insufficient aldosterone production) and androgen excess, caused by deficiency in one of the enzymes responsible for cholesterol degradation (1, 2).”
BackgroundPauwels, G., Allegaert, K., Régal, L., & Meulemans, A. (2012) · PubMed · doi:10.2143/acb.67.2.2062637 · Cited by 6
“Day of sampling (day of postnatal life) 3 (2-23) 3 (2-7) 0.”
BackgroundMethodDörr, H. G., Odenwald, B., & Nennstiel, U. (2015) · International Journal of Neonatal Screening · doi:10.3390/ijns1010036 · Cited by 8
Zhang, Q., Zhan, M., Wu, H., Feng, P., Jin, X., Wan, Z., Yan, J., Zhang, P., Ke, P., Zhuang, J., et al. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2022.961660 · Cited by 5
“Despite the elevation of 17OHP level being mostly considered as the primary indicator for determining 21-hydroxylase deficiency, other forms of CAH may also lead to the change of 17OHP level (Schwarz et al., 2009).”
BackgroundYoon, Y. A., Woo, S., Kim, M. S., Kim, B., & Choi, Y. (2023) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2022-8399 · Cited by 7
The role of steroid metabolome analysis for the diagnosis and follow-up of adrenocortical tumors
Chortis, V. (2018) · Minerva Endocrinology · doi:10.23736/s0391-1977.18.02869-9 · Cited by 5
Multiple 17-OHP Cutoff Co-Variates Fail to Improve 21-Hydroxylase Deficiency Screening Accuracy
Matharu, P. K., Held, P. K., & Allen, D. B. (2022) · International Journal of Neonatal Screening · doi:10.3390/ijns8040057 · Cited by 5
Tajima, T. (2024) · Clinical Pediatric Endocrinology · doi:10.1297/cpe.2024-0069 · Cited by 5
Yamano, H., Watanabe, K., Komatsu, M., Hashimoto, A., Suzuki, Y. Y., Kirino, S., Saito, Y., Adachi, E., Gau, M., Nakatani, H., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf506 · Cited by 2
Ionova, T. A., Калинченко, Н. Ю., Tiulpakov, A. N., & Nizhnik, A. N. (2013) · Problems of Endocrinology · doi:10.14341/probl201359212-18 · Cited by 4
Clinical Analysis by Mass Spectrometry
Prabhu, G. R. D., Elpa, D. P., Chiu, H., & Urban, P. L. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.14219-2 · Cited by 2
Bioanalytical Method Development: Considering Information From A Suite of Complementary Methods
Fountain, M. E. (2012) · Bioanalysis · doi:10.4155/bio.11.307 · Cited by 1
Jäntti, S. E. (2013) · Helda - University of Helsinki Institutional Repository · Cited by 1
Predictive Value of Steroidal Hormones to Type 2 Diabetes and Metabolic Syndrome
Bunch, D. R. (2016) · OhioLink ETD Center (Ohio Library and Information Network)
Hayashi, G. Y. (2016) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.5.2016.tde-06062016-120400
de Carvalho, D. F. (2017) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2017.tde-04082017-113148
Ultra-high Performance Liquid Chromatography in Steroid Analysis
Salonen, F. (2017) · Työväentutkimus Vuosikirja
de Miranda, M. C. (2020) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2020.tde-29102020-162042
Drake, W. M., Keevil, B. G., & Trainer, P. J. (2022) · doi:10.1093/med/9780198870197.003.0006
Current literature in mass spectrometry
(2010) · Journal of Mass Spectrometry · doi:10.1002/jms.1643
(2010) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e328339f31e
Honour, J. W. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-818124-9.00004-8
Mass Spectrometry-Based Metabolomics for the Clinical Laboratory
Dubland, J. A. (2023) · Springer eBooks · doi:10.1007/978-981-99-5162-8_2
Li, Z., Liang, Y., Du, C., Yu, X., Hou, L., Wu, W., Ying, Y., & Luo, X. (2021) · Figshare · doi:10.6084/m9.figshare.17083928
Li, Z., Liang, Y., Du, C., Yu, X., Hou, L., Wu, W., Ying, Y., & Luo, X. (2021) · Figshare · doi:10.6084/m9.figshare.17083925
Li, Z., Liang, Y., Du, C., Yu, X., Hou, L., Wu, W., Ying, Y., & Luo, X. (2021) · Figshare · doi:10.6084/m9.figshare.17083931
A Two-Step LC-MS/MS method to differentiate 21OHD and PORD in Screen-Positive newborns
Nakatani, H., Watanabe, K., Tsuji‐Hosokawa, A., Sutani, A., Saito, Y., Kirino, S., Yamano, H., Orimoto, R., Gau, M., Yogi, A., et al. (2026) · Endocrine · doi:10.1007/s12020-026-04573-z
Metadata
- Authors
- Schwarz, E., Liu, A., Randall, H., Haslip, C., Keune, F., Murray, M., Longo, N., & Pasquali, M.
- Affiliations
- ARUP Institute for Clinical and Experimental Pathology (US)
- Utah Department of Health (US)
- ARUP Laboratories (United States) (US)
- University of Utah (US)
- Corresponding author
- Schwarz, Elisabeth
- Venue
- Pediatric Research
- Published
- 2009-08
- Volume
- 66
- Issue
- 2
- Pages
- 230-235
- ISSN
- 0031-3998 (ISSN-L)
- 1530-0447
- OpenAlex
- W2005997531
- Cited by
- 97
- References
- 24
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 3 · 2023: 6 · 2022: 8 · 2021: 11 · 2020: 8 · 2019: 3 · 2018: 4 · 2017: 5 · 2016: 4 · 2015: 8 · 2014: 4 · 2013: 7 · 2012: 8
- FWCI
- 3.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Pediatric Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Utah Department of Health
- ARUP Institute for Clinical and Experimental Pathology
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Keywords
- congenital adrenal hyperplasia, newborn screening, steroid profiling, UPLC-MS/MS, 17-hydroxyprogesterone, androstenedione, cortisol, false positive reduction, salt-wasting CAH, simple virilizing CAH, birth weight
- MeSH terms
- Adrenal Hyperplasia, Congenital, Androstenedione, Chromatography, High Pressure Liquid, Female, Humans, Hydrocortisone, Infant, Infant, Newborn, Male, Utah, Neonatal Screening, 17-alpha-Hydroxyprogesterone, Tandem Mass Spectrometry
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.